A putative therapeutic target in Pompe disease: P10253

Ablatotech Signals reports today on a putative therapeutic target — P10253 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in Pompe disease.

Background

Pompe disease, a rare lysosomal storage disorder caused by the deficiency of the enzyme acid alpha-glucosidase, leads to the accumulation of glycogen in tissues, particularly affecting muscle function. The putative target P10253, identified through data mining efforts, presents a potential avenue for therapeutic exploration in Pompe disease. This candidate warrants further investigation to elucidate its role in disease pathology and potential as a therapeutic target.

Data-mining rationale

The identification of P10253 as a putative target was achieved by cross-referencing UniProt's reviewed human entries for "Pompe disease" with seven microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate appears in expression-profiling studies, indicating a possible involvement in the disease mechanism. However, it is noteworthy that there are no registered Phase 1 or higher clinical programs associated with this target in our current scan.

Why prior analyses may have missed this

Many of the GEO datasets utilized in this analysis predate modern empirical-Bayes statistical methods, such as limma, which are crucial for robust data interpretation. These earlier analyses may not have adequately accounted for multiple testing corrections, potentially leading to overlooked candidates like P10253. The re-analysis of these datasets using contemporary statistical approaches could yield new insights into the expression patterns and biological significance of this target in Pompe disease.

Reasoning for further validation

To substantiate the potential role of P10253 in Pompe disease, several experimental approaches are suggested: 1. Re-analyze the matched GEO datasets employing the limma package with Benjamini-Hochberg false discovery rate (FDR) set to less than 0.05 to identify differentially expressed genes accurately. 2. Validate the top differentially expressed genes through quantitative PCR (qPCR) in an independent cohort to confirm their expression levels. 3. Investigate tissue specificity of P10253 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas. 4. Utilize pathway analysis tools like STRING and OmniPath to explore the biological context and interactions of P10253 within relevant pathways. 5. If validation is achieved, assess the druggability of P10253 using databases such as DGIdb and ChEMBL to evaluate its potential as a therapeutic target.

References